Axoft, a Cambridge, MA-based developer of bioinspired ultra-soft neural implants, has raised $55M in Series A funding led by C.P. Group Innovation. The company builds Fleuron probes that mimic brain tissue for long-term, high-density bidirectional brain communication at single-neuron resolution. The capital will fund global clinical trials, U.S. FDA approval, and a GMP manufacturing facility.
BCI Funding Hits $1.75B in 12 Months
Axoft's raise joins a surge where brain-computer interface firms secured $1.75B across 17 companies over the past year. Neuralink closed a $650M Series E, while Synchron raised $200M Series D in November 2025. Precision Neuroscience added $41M recently. Axoft targets stability issues plaguing rigid implants with its tissue-like softness.
Rigid Implants Cause Signal Drift
Current neural interfaces suffer from tissue scarring and motion artifacts that degrade signals over time. Rigid electronics, even flexible ones, move relative to brain tissue, requiring complex correction algorithms. This limits long-term single-neuron recording essential for treating paralysis, epilepsy, and coma. Axoft's approach minimizes invasiveness via a 2mm insertion hole.
Fleuron Probes Mimic Brain Tissue
Axoft's Fleuron ultrasoft probes are 1,000,000x softer than traditional rigid electronics and 1000x denser in electrodes than other soft competitors, per company data. Deployed through minimally invasive surgery, they integrate seamlessly without drift. The implants enable high-bandwidth recording and stimulation, paired with Brain Foundation Model software for decoding. First human implants occurred in April 2025, with 11 patients across three sites by April 2026.
As Dr. Paul Le Floch, CEO noted:
"At Axoft, the neural data quality we unlock doesn't just make iBCIs more effective… Better neural signals are the foundation everything else is built on."
Strategic Investors Back Clinical Push
C.P. Group Innovation led the oversubscribed round, joined by Alumni Ventures, Stanford President’s Venture Fund, Hillhouse Investment, and Gaorong Ventures. Total funding exceeds $60M including an $8M seed in 2022. These backers signal conviction in Axoft's path to commercialization amid FDA Breakthrough Device designation. The mix blends deep-tech VCs with strategic funds tied to academia and Asia.
Brain Implants Market Doubles by 2030
The brain implants market stands at $6.38B in 2024, projected to reach $11.20B by 2030 at 9.7% CAGR. Rising neurological disorders drive demand for stable BCIs. Competitors like Paradromics focus on bandwidth, but Axoft prioritizes biocompatibility for chronic use.
Human trials accelerate, with ten BCI companies now implanting patients. Soft materials emerge as key to reducing damage, positioning Axoft advantageously.
Harvard Lab Spins Out Serial Founder
Axoft stems from Harvard's Jia Liu lab, where co-founders Paul Le Floch (CEO) and Tianyang Ye (CTO) invented the core tech as PhD students. Scientific advisor Jia Liu, a Harvard professor with MIT TR35 and NIH awards, pioneered tissue-integrated bioelectronics. Le Floch earned Forbes 30 Under 30. The team includes clinical experts like Oliver Armitage from BIOS Health.
Global Trials and GMP Scale-Up
Funds enable expansion of FINESSE first-in-human studies with partners like Mass General Brigham and Panama Clinic. Axoft plans U.S. FDA submission and GMP facility buildout, backed by a $835K Massachusetts grant. Active hiring for firmware, software, and manufacturing roles supports this shift to clinical production.